Erythropoietin in the Treatment of Anemia After Autologous Hematopoietic Stem Cell Transplantation

Efficacy and Safety of Erythropoietin in the Treatment of Anemia in Patients With Lymphoma After Autologous Hematopoietic Stem Cell Transplantation

This is an randomized trial to evaluate the potential benefit of erythropoietin in the treatment of anemia in patients with lymphoma after autologous hematopoietic stem cell transplantation.

Lymphoma patients with anemia on day +15 post-transplant will be randomized to erythropoietin group or control group. Potential benefit of erythropoietin will be evaluatedon day +60 post-transplant.

Inclusion Criteria:

• confirmed lymphoma
• first autologous hematopoietic stem cell transplantation
• hemoglobin level less than 100 g/L on day +15 post-transplant
• written informed consent given by patient or his/her guardian if of minor age.

Exclusion Criteria:

• HIV positive
• Known allergy to recombinant human erythropoietin
• Uncontrolled infection